A 20-Year Temporal Change Analysis in Incidence, Presenting Phenotype and Mortality, in the Dutch IBDSL Cohort—Can Diagnostic Factors Explain the Increase in IBD Incidence?

Heuvel, Tim R A van den; Dongen, Dorien H E van; Wolters, Anouk; Masclee, Ad; Hameeteman, Wim; Romberg‐Camps, Mariëlle; Oostenbrug, Liekele E.; Pierik, Marieke; Jonkers, Daisy

doi:10.1093/ecco-jcc/jjx055

Cited by 41 publications

(27 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recent Dutch IBD data representing chronological changes indicated that the number of mild ulcerative colitis and ulcerative proctitis has increased [5]. In pediatric patients, 25% of patients had ulcerative proctitis [6].…”

Section: Epidemiologymentioning

confidence: 99%

Optimized Management of Ulcerative Proctitis: When and How to Use Mesalazine Suppository

et al. 2018

View full text Add to dashboard Cite

Background: Ulcerative proctitis, one of the disease types of ulcerative colitis, is considered one of the initial manifestations of ulcerative colitis. Prevention of aggravation of ulcerative proctitis is important for improving the prognosis of ulcerative colitis. Here we reviewed the epidemiology, diagnosis, and management of ulcerative proctitis. Summary: The number of patients with ulcerative proctitis is increasing. Disease extension occurs in many patients with ulcerative proctitis. Differential diagnosis from other chronic proctitis is important and should be performed based on the clinical history and endoscopical and histological features. Mesalazine suppository has been the first-line therapy for patients with ulcerative proctitis because of its high effectiveness and safety. Topical treatment of ulcerative proctitis, particularly using mesalazine suppository has been underused in clinical practice. Key Messages: Mesalazine suppositories are more effective than dose intensification of oral mesalazine for relapsed patients with maintenance dose of oral mesalazine. However, low adherence to rectal mesalazine has hindered remission in patients with ulcerative proctitis.

show abstract

Section: Epidemiologymentioning

confidence: 99%

Optimized Management of Ulcerative Proctitis: When and How to Use Mesalazine Suppository

et al. 2018

View full text Add to dashboard Cite

show abstract

“…8 In the Dutch IBDSL cohort, the incidence of CD and UC rose from 5.84 and 11.67, respectively, per 100,000 in 1991 to 17.49 and 21.47 in 2010, corresponding to an average annual percentage change (AAPC) of +5.97% and + 3.79%. 9 Within Europe, the incidence of IBD is characterized by a north-south and an east-west gradient, where the incidence of CD was 6.3 per 100,000 in Northern Europe in comparison to only 3.6 per 100,000 in Southern Europe, and the incidence of UC in Northern and Southern Europe was 11.4 and 8.0 per 100,000, respectively. 10 Finally, during the last decade, a significant rise in IBD has been observed in Eastern Europe.…”

Section: Introductionmentioning

confidence: 99%

The epidemiology of inflammatory bowel disease: East meets west

Mak

Zhao

et al. 2019

J of Gastro and Hepatol

365

225

View full text Add to dashboard Cite

The incidence of inflammatory bowel diseases (IBD) in East has risen over the past decade to become a global disease. The increasing number of studies on the incidence and course of IBD in East has enabled us to explore East versus West differences in the epidemiology of IBD which could enhance our understanding of the heterogeneity of the disease and eventually assist in the discovery of novel therapeutic targets and design of preventive strategies. Comparison of population‐based data in East and West reveals that the incidence of IBD has risen rapidly in East while plateauing in West. Furthermore, the clinical presentation and course of IBD differs between East and West with more patients in East presenting with complicated disease. Considering the scarcity of population‐based data from East and the lack of studies with long durations of follow‐up, it remains to be clarified whether these differences reflect true differences in disease presentation. The effects of genetic and environmental risk factors contributing to IBD also differ between Eastern and Western populations. Considering the differential effects of genetic and environmental risk factors in East and West, future studies should seek to discover novel genetic and environmental risk factors which might specifically apply to eastern populations. In this narrative review, we compare the epidemiology of IBD between eastern and western countries by summarizing evidence from population‐based cohort studies in the last ten years. Furthermore, we look at differences in genetic susceptibility and environmental triggers of IBD between East and West.

show abstract

“…Crohn's disease (CD) is a chronic autoimmune disease of the digestive tract, with poorly understood aetiopathogenesis. In the last 20 years there has been a significant increase in the incidence of inflammatory bowel disease (IBD) [1,2]. During exacerbation, mainly steroids are used, which do not allow achievement of long-term remission, often causing dependence and significant side effects (SE) [3].…”

Section: Introductionmentioning

confidence: 99%

Efficiency and safety of one-year anti-TNF-α treatment in Crohn’s disease: a Polish single-centre experience

Sochal¹,

Krzywdzińska²,

Gabryelska³

et al. 2020

View full text Add to dashboard Cite

Introduction: Anti-TNF-α therapy of Crohn's disease (CD) represents considerable progress in inflammatory bowel disease (IBD) treatment; however, many patients still require surgical intervention. The Polish National Insurance Fund currently only covers up to 2 years of infliximab (IFX) therapy in CD patients and 1 year of adalimumab (ADA). Aim: To estimate the effectiveness and side effects of the anti-TNF-α Polish therapeutic program in CD patients. Material and methods: In this retrospective study, medical documentation of 80 CD patients treated with anti-TNF-α (IFX or ADA) was analysed. Fifty-two patients finished 1 year of therapy, and 28 individuals did not complete it due to lack of response to treatment or severe side effects. Results: After treatment, 27 (67.50%) patients achieved a semi-annual remission and 14 (35%) achieved yearly remission. Twenty percent of patients experienced severe side effects such as anaphylactic shock, pneumonia, shingles, or upper respiratory tract infections. A strong negative correlation between the number of patients in remission and the period since therapy termination (r =-0.996, p < 0.001) was found. During the 1-year follow-up, 20 patients were re-enrolled in the biological therapy program (the median time to next therapy was 231 days IQR: 126.5-300.5) Conclusions: Anti-TNF-α treatment in CD is relatively safe. The restricted time period of the therapy affects the clinical course of the disease and entails the need to resume biological therapy.

show abstract

A 20-Year Temporal Change Analysis in Incidence, Presenting Phenotype and Mortality, in the Dutch IBDSL Cohort—Can Diagnostic Factors Explain the Increase in IBD Incidence?

Cited by 41 publications

References 46 publications

Optimized Management of Ulcerative Proctitis: When and How to Use Mesalazine Suppository

Optimized Management of Ulcerative Proctitis: When and How to Use Mesalazine Suppository

The epidemiology of inflammatory bowel disease: East meets west

Efficiency and safety of one-year anti-TNF-α treatment in Crohn’s disease: a Polish single-centre experience

Contact Info

Product

Resources

About